Please login to the form below

Not currently logged in
PMLiVE Top Pharma List


Revenue 2017


The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Soliris was produced by Alexion.

Assessing drugs for ultra-rare conditions in the UK

Assessing drugs for ultra-rare conditions in the UK Along the way Soliris underwent review by the now-defunct Advisory Group for National Specialised Services (AGNSS). ... Nevertheless, if it needed convincing about Soliris' cost, NICE was impressed with the drug's benefits.

NICE set to back Alexion's costly 'ultra-orphan' drug

NICE set to back Alexion's costly 'ultra-orphan' drug on high cost drugs - and Soliris' price has previously been a problem for NICE. ... Alexion estimated Soliris produced 25.22 additional QALYs per patient compared with standard care.

Alexion convinces NICE of Soliris' value

Alexion convinces NICE of Soliris' value Alexion's high cost rare disease drug Soliris has been recommended by NICE for use in England under its new approach to highly specialised technologies. ... Soliris (eculizumab) is licensed to treat atypical hemolyic uremic syndrome (aHUS) drug, a

NICE and ‘ultra orphans’

NICE and ‘ultra orphans’ NICE expects to issue its guidance on Soliris by July 2014 and in the meantime NHS England will continue to fund the drug's use for new and existing aHUS patients. ... Soliris remains the only drug so far to be put through NICE's highly specialised

NICE: Alexion must justify Soliris' high cost

NICE: Alexion must justify Soliris' high cost At current disease levels the total NHS spend on Soliris (eculizumab) would be £58m in the first year, rising to £80m over five years at predicted diagnosis rates. ... In its response, Alexion said it was “pleased” that NICE has reaffirmed the

[ Previous 5 results ] 2 3 4 5 6 7 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts


Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....
The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....